Novo Nordisk A/S, Eli Lilly and Company and Sanofi Accounts for More Than Half of the Market Share in Terms of Revenue
Accessibility of low-priced Insulin supported by growing investments in R&D is likely to boost the growth of insulin segment in the global diabetes drugs market
Format
PNG
Source
Fortune Business Insights